The most frequently used molecular imaging technique is currently 18F-deoxy-glucose (FDG) positron emission tomography (PET). FDG-PET holds promise in the evaluation of recurrent or residual ovarian cancer when CA125 levels are rising and conventional imaging, such as ultrasound, CT, or MRI, is inconclusive or negative. Recently, integrated PET/CT, in which a full-ring-detector clinical PET scanner and a multidetector helical CT scanner are combined, has enabled the acquisition of both metabolic and anatomic imaging data using one device in a single diagnostic session. This can also provide precise anatomic localization of suspicious areas of increased FDG uptake and rule out false-positive PET findings. FDG-PET/CT is an accurate modality for assessing primary and recurrent ovarian cancer and may affect management. FDG-PET/CT may provide benefits for detection of recurrent of ovarian cancer and improve surgical planning. And FDG-PET has been shown to predict response to neoadjuvant chemotherapy and survival in advanced ovarian cancer. This review focuses on the role of FDG-PET and FDG-PET/CT in the management of patients with ovarian cancer. Recently, we have evaluated 16α-18F-fluoro-17β-estradiol (FES)-PET, which detects estrogen receptors. In a preliminary study we reported that FES-PET provides information useful for assessing ER status in advanced ovarian cancer. This new information may expand treatment choice for such patients.
Kikuchi-Fujimoto disease (KFD), formerly called subacute necrotizing lymphadenitis, is a rare cause of cervical lymphadenopathy. The purpose of this study was to evaluate the usefulness of FDG PET/CT for distinguishing KFD from non-Hodgkin lymphoma (NHL). Twenty-two patients with cervical lymphadenopathy (8 with KFD and 14 with NHL) underwent CT and FDG PET/CT scans to examine the cervical lymphadenopathy. Regional values of FDG uptake were evaluated using the standardized uptake value (SUV) and partial volume corrected SUV (corSUV) based on the count recovery coefficient. Tumor size (mm), SUV, and corSUV were compared among KFD, indolent NHL, and aggressive NHL. KFD lesions tended to be smaller (13.8 ± 5.4 mm) than those of indolent (25.4 ± 11.8) and aggressive (29.7 ± 18.8) NHL, whereas there were no significant differences in size. As for SUV, a significant difference was observed only between indolent and aggressive (6.4 ± 1.5 and 17.3 ± 9.3, P < 0.05) NHL; however, KFD showed a significantly greater corSUV (23.8 ± 10.6) as compared with indolent NHL (9.2 ± 5.1, P < 0.05), which did not show a significant difference from aggressive NHL (21.4 ± 10.2). FDG PET/CT detected thoracoabdominal lesions in 2 patients (25%) with KFD. KFD shows high FDG uptake for size, which may reflect the pathologic characteristics, including necrotizing lymphocytes and numerous histiocytes (macrophages) surrounding small necrotic foci. FDG PET/CT will be useful for detecting noncervical lesions of KFD and distinguishing KFD from NHLs using both SUV and corSUV.
The purpose of this study was to prospectively determine whether combined MRI and 18F-FDG PET is more accurate than MRI in assessing nonbenign uterine smooth muscle tumors (USMTs). Methods: Seventy patients (mean age, 49 ± 10 y; range, 28–77 y) suspected of having nonbenign USMTs underwent both MRI and 18F-FDG PET before surgery. Results were evaluated using receiver-operating-characteristic (ROC) analyses and the Cochran Q test. Results: The area under the ROC curve for MRI with 18F-FDG PET was significantly higher than that for MRI (0.97 vs. 0.89, P < 0.05). Although multiple comparisons using the Cochran Q test were not significant, the sensitivity, specificity, and accuracy for MRI with 18F-FDG PET with probable nonbenign USMT cases considered to be positive were higher than those for MRI (93.3% vs. 73.3%; 92.7% vs. 85.5%; and 92.9% vs. 82.9%, respectively). Conclusion: MRI with 18F-FDG PET is useful in assessing nonbenign USMTs, as compared with MRI.